SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 5, 2013, Pages 524-531

  Malhotra, S ^a   Castillo J ^a   Bustamante, M F ^a   Vidal Jordana, A ^a   Castro, Z ^a   Montalban, X ^a   Comabella, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

acute relapses; biomarkers; disease progression; monocytes; Multiple sclerosis; SIGLEC1; SIGLEC7

Indexed keywords

CD14 ANTIGEN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 7; SIALOADHESIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION;

EID: 84876576936     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512458718     Document Type: Article

References (16)

1. May AP, Robinson RC, Vinson M, et al. Crystal structure of the N-terminal domain of sialoadhesin in complex with 3- sialyllactose at 1.85 A resolution. Mol Cell. 1998 ; 1: 719-728
2. Varki A, Angata T. Siglecs-the major subfamily of I-type lectins. Glycobiology. 2006 ; 16: 1R - 27R
3. Crocker P, Clark E, Filbin M, et al. Siglecs: a family of sialic-acid binding lectins. Glycobiology. 1998 ;:
4. Hartnell A, Steel J, Turley H, et al. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood. 2001 ; 97: 288-296
5. York MR, Nagai T, Mangini AJ, et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum. 2007 ; 56: 1010-1020
6. Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum. 2008 ; 58: 1136-1145
7. Bao G, Han Z, Yan Z, et al. Increased Siglec-1 expression in monocytes of patients with primary biliary cirrhosis. Immunol Invest. 2010 ; 39: 645-660
8. Malhotra S, Bustamante MF, Pérez-Miralles F, et al. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis. PLoS One. 2011 ; 6: e23634
9. Orr SJ, Morgan NM, Buick RJ, et al. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J Biol Chem. 2007 ; 282: 3418-3422
10. Baker BJ, Akhtar LN, Benveniste EN. SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol. 2009 ; 30 (8). 392-400
11. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001 ; 25: 402-408
13. Pillai S, Netravali IA, Cariappa A, et al. Siglecs and immune regulation. Annu Rev Immunol. 2012 ; 30: 357-392
14. Hendriks JJ, Teunissen CE, De Vries HE, et al. Macrophages and neurodegeneration. Brain Res Rev. 2005 ; 48: 185-195
15. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005 ; 5: 953-964
16. Frisullo G, Mirabella M, Angelucci F, et al. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2007 ; 192: 174-183